Perspective Therapeutics, Inc. (CATX)
| Market Cap | 440.22M +146.6% |
| Revenue (ttm) | 618,000 -58.0% |
| Net Income | -111.13M |
| EPS | -1.36 |
| Shares Out | 114.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 834,520 |
| Open | 3.850 |
| Previous Close | 3.820 |
| Day's Range | 3.710 - 3.950 |
| 52-Week Range | 1.955 - 6.160 |
| Beta | 1.76 |
| Analysts | Strong Buy |
| Price Target | 12.11 (+213.73%) |
| Earnings Date | May 11, 2026 |
About CATX
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-α-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2... [Read more]
Financial Performance
In 2025, Perspective Therapeutics's revenue was $884,000, a decrease of -39.20% compared to the previous year's $1.45 million. Losses were -$103.12 million, 30.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price target is $12.11, which is an increase of 213.73% from the latest price.
News
Perspective Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Four clinical programs are advancing, with VMT-α-NET showing strong efficacy and safety, and pivotal trial planning underway. Manufacturing expansion and robust cash reserves support continued growth, while additional pipeline assets and new facilities position the company for broad market impact.
Perspective Therapeutics price target lowered to $6 from $7 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Perspective Therapeutics (CATX) to $6 from $7 and keeps a Neutral rating on the shares. The Q1 report reinforced the…
Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)
Reports Q1 revenue $76,000, consensus $137,180. “The first quarter of 2026 was marked by continued execution across our clinical programs and strengthening of our financial position,” said Thijs Spoor...
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
SEATTLE, May 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneeri...
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme...
Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET
Perspective Therapeutics (CATX) announced updated interim results from its ongoing Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor t...
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
SEATTLE, April 20, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatmen...
Perspective Therapeutics to Participate in Upcoming Investor Conferences
SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme...
Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Perspective Therapeutics (CATX) to $13 from $12 and keeps a Buy rating on the shares. The firm updated the company’s model post…
Perspective Therapeutics price target raised to $8 from $7 at UBS
UBS analyst David Dai raised the firm’s price target on Perspective Therapeutics (CATX) to $8 from $7 and keeps a Buy rating on the shares.
Perspective Therapeutics price target raised to $13 from $11 at B. Riley
B. Riley raised the firm’s price target on Perspective Therapeutics (CATX) to $13 from $11 and keeps a Buy rating on the shares. Sentiment on Perspective Therapeutics has sharply improved…
Perspective Therapeutics price target raised to $8 from $7 at UBS
UBS analyst David Dai raised the firm’s price target on Perspective Therapeutics (CATX) to $8 from $7 and keeps a Buy rating on the shares.
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme...
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
SEATTLE, March 16, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pionee...
Perspective Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler analyst Biren Amin initiated coverage of Perspective Therapeutics (CATX) with an Overweight rating and $16 price target The firm says the company’s pipeline of lead-212 radiotherapies po...
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatmen...
Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering
Perspective Therapeutics (CATX) announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in…
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments f...
Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Perspective Therapeutics (CATX) to $12 from $10 and keeps a Buy rating on the shares. The firm says Sanofi’s deprioritization of Alphamedix…
Perspective Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant clinical progress was reported across neuroendocrine, melanoma, and FAP-α programs, with strong efficacy, safety, and patient selection enabled by proprietary technology. Vertically integrated manufacturing and robust supply chain support scalability, while a strong cash position and multiple 2026 data catalysts position the company for growth.
Perspective Therapeutics provides business updates, strategic priorities
Perspective Therapeutics (CATX) announced certain business updates and strategic priorities for the next 12-18 months. Key updates include: Continued strong patient recruitment in neuroendocrine tumor...
Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET
Perspective Therapeutics (CATX) announced updated interim results from its ongoing Phase 1/2a clinical trial of 212PbVMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor typ...
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
SEATTLE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is...
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatmen...
Perspective Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing radiopharmaceutical therapies with a proprietary chelator and Lead-212 platform, showing strong efficacy and safety in SSTR2-positive neuroendocrine tumors. Additional programs targeting MC1R and FAP are progressing, with robust financials and manufacturing capacity supporting growth.